Edition:
United States

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

4.12USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$4.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
112,942
52-wk High
$7.67
52-wk Low
$3.92

Select another date:

Thu, Jan 11 2018

BRIEF-Elanco, Aratana Announce Marketing Authorization Of Galliprant In Europe

* ELANCO, ARATANA ANNOUNCE MARKETING AUTHORIZATION OF GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE Source text for Eikon: Further company coverage:

BRIEF-Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic

* ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC

BRIEF-Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria

* ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY

BRIEF-Aratana Therapeutics Announces Proposed Public Offering

* ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

BRIEF-ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE

* ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE

BRIEF-Aratana Therapeutics reports Q3 loss per share of $0.21

* Aratana Therapeutics reports third quarter 2017 financial results

BRIEF-Aratana Therapeutics announces launch of Entyce

* Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution)

Select another date: